These two drugs target EGFR, which is highly expressed in the SUM149 cell line [60, 61], and, along with the finding that EGFR signaling plays a role in IBC progression and metastasis and can be blocked by EGFR inhibition [62], likely explains the effectiveness of these drugs in SUM149. This evidence concerns the gene EGFR and inflammatory breast carcinoma.